Inactivated influenza virus vaccines: the future of TIV and QIV

Current Opinion in Virology

Volumn 23, Issue , 2017, Pages 102-106

  Schotsaert, Michael ^a   García Sastre, Adolfo ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; QUADRIVALENT INACTIVATED INFLUENZA VACCINE; SIALOPROTEIN; TRIVALENT INACTIVATED INFLUENZA VACCINE; UNCLASSIFIED DRUG; INACTIVATED VACCINE; LIVE VACCINE;

ANTIBODY RESPONSE; ANTIGENIC MODULATION; BINDING SITE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE EVASION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS ATTACHMENT; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; COMPARATIVE STUDY; IMMUNOLOGY;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 85019161262     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2017.04.005     Document Type: Review

References (48)

1. Sandoval, C., Barrera, A., Ferres, M., Cerda, J., Retamal, J., Garcia-Sastre, A., Medina, R.A., Hirsch, T., Infection in health personnel with high and low levels of exposure in a hospital setting during the H1N1 2009 influenza A pandemic. PLoS One, 11, 2016, e0147271.
2. Ambrose, C.S., Levin, M.J., The rationale for quadrivalent influenza vaccines. Hum. Vaccines Immunother. 8 (2012), 81–88.
3. Maassab, H.F., Heilman, C.A., Herlocher, M.L., Cold-adapted influenza viruses for use as live vaccines for man. Adv. Biotechnol. Processes 14 (1990), 203–242.
4. Hovden, A.O., Cox, R.J., Haaheim, L.R., Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand. J. Immunol. 62 (2005), 36–44.
5. Clements, M.L., Betts, R.F., Tierney, E.L., Murphy, B.R., Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24 (1986), 157–160.
6. Belongia, E.A., Simpson, M.D., King, J.P., Sundaram, M.E., Kelley, N.S., Osterholm, M.T., McLean, H.Q., Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect. Dis. 16 (2016), 942–951.
7. Ambrose, C.S., Levin, M.J., Belshe, R.B., The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir. Viruses 5 (2011), 67–75.
8. Kolpe, A., Schepens, B., Fiers, W., Saelens, X., M2-based influenza vaccines: recent advances and clinical potential. Expert Rev. Vaccines 16 (2017), 123–136.
9. Berlanda Scorza, F., Tsvetnitsky, V., Donnelly, J.J., Universal influenza vaccines: shifting to better vaccines. Vaccine 34 (2016), 2926–2933.
10. Krammer, F., Palese, P., Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3 (2013), 521–530.
11. Krammer, F., Novel universal influenza virus vaccine approaches. Curr. Opin. Virol. 17 (2016), 95–103.
12. LaMere, M.W., Lam, H.T., Moquin, A., Haynes, L., Lund, F.E., Randall, T.D., Kaminski, D.A., Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186 (2011), 4331–4339.
13. Ulmer, J.B., Donnelly, J.J., Parker, S.E., Rhodes, G.H., Felgner, P.L., Dwarki, V.J., Gromkowski, S.H., Deck, R.R., DeWitt, C.M., Friedman, A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993), 1745–1749.
14. Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W.M., Fiers, W., A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5 (1999), 1157–1163.
15. 15• Wohlbold, T.J., Nachbagauer, R., Xu, H., Tan, G.S., Hirsh, A., Brokstad, K.A., Cox, R.J., Palese, P., Krammer, F., Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio, 6, 2015, e02556 This study shows that vaccine-induced immunity to the influenza neuraminidase can broaden protection against different influenza virus strains.
16. 16• Jegaskanda, S., Co, M.D., Cruz, J., Subbarao, K., Ennis, F.A., Terajima, M., Human seasonal influenza A viruses induce H7N9-cross-reactive antibody-dependent cellular cytotoxicity (ADCC) antibodies that are directed towards the nucleoprotein. J. Infect. Dis. 215 (2016), 818–823 This study illustrates that antibodies against internal viral proteins like the nucleoprotein can be induced and detected in humans.
17. Jegaskanda, S., Luke, C., Hickman, H.D., Sangster, M.Y., Wieland-Alter, W.F., McBride, J.M., Yewdell, J.W., Wright, P.F., Treanor, J., Rosenberger, C.M., et al. Generation and protective ability of influenza virus-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection, and experimental challenge. J. Infect. Dis. 214 (2016), 945–952.
18. Jegaskanda, S., Job, E.R., Kramski, M., Laurie, K., Isitman, G., de Rose, R., Winnall, W.R., Stratov, I., Brooks, A.G., Reading, P.C., et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190 (2013), 1837–1848.
19. Leon, P.E., He, W., Mullarkey, C.E., Bailey, M.J., Miller, M.S., Krammer, F., Palese, P., Tan, G.S., Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E5944–E5951.
20. Van den Hoecke, S., Ehrhardt, K., Kolpe, A., El Bakkouri, K., Deng, L., Grootaert, H., Schoonooghe, S., Smet, A., Bentahir, M., Roose, K., et al. Hierarchical and redundant roles of activating FcgammaRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies. J. Virol. 91 (2017), e02500–16.
21. El Bakkouri, K., Descamps, F., De Filette, M., Smet, A., Festjens, E., Birkett, A., Van Rooijen, N., Verbeek, S., Fiers, W., Saelens, X., Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186 (2011), 1022–1031.
22. Greenbaum, J.A., Kotturi, M.F., Kim, Y., Oseroff, C., Vaughan, K., Salimi, N., Vita, R., Ponomarenko, J., Scheuermann, R.H., Sette, A., et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 20365–20370.
23. Wilkinson, T.M., Li, C.K., Chui, C.S., Huang, A.K., Perkins, M., Liebner, J.C., Lambkin-Williams, R., Gilbert, A., Oxford, J., Nicholas, B., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18 (2012), 274–280.
24. Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., Bean, T., Barclay, W., Deeks, J.J., Lalvani, A., Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19 (2013), 1305–1312.
25. Cowling, B.J., Ng, S., Ma, E.S., Cheng, C.K., Wai, W., Fang, V.J., Chan, K.H., Ip, D.K., Chiu, S.S., Peiris, J.S., et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin. Infect. Dis. 51 (2010), 1370–1379.
26. 26• Mohn, K.G., Bredholt, G., Brokstad, K.A., Pathirana, R.D., Aarstad, H.J., Tondel, C., Cox, R.J., Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. J. Infect. Dis. 211 (2015), 1541–1549 In this study it is shown that LAIV can induce long-lasting (>1year) B and T cell responses in children, thereby providing evidence that LAIV can be a good influenza vaccine for this age group.
27. Hoft, D.F., Lottenbach, K.R., Blazevic, A., Turan, A., Blevins, T.P., Pacatte, T.P., Yu, Y., Mitchell, M.C., Hoft, S.G., Belshe, R.B., Comparisons of the humoral and cellular immune responses induced by live attenuated influenza vaccine and inactivated influenza vaccine in adults. Clin. Vaccine Immunol., 24, 2017.
28. 28• Sasaki, S., Holmes, T.H., Albrecht, R.A., Garcia-Sastre, A., Dekker, C.L., He, X.S., Greenberg, H.B., Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines. J. Infect. Dis. 210 (2014), 865–874 The authors show that vaccination with LAIV can result in proportionally more cross-reactive plasmablast responses compared to vaccination with inactivated influenza virus vaccines.
29. Music, N., Reber, A.J., Kim, M.C., York, I.A., Kang, S.M., Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets. Vaccine 34 (2016), 466–473.
30. Song, J.M., Van Rooijen, N., Bozja, J., Compans, R.W., Kang, S.M., Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 757–761.
31. Budimir, N., de Haan, A., Meijerhof, T., Gostick, E., Price, D.A., Huckriede, A., Wilschut, J., Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration. Influenza Other Respir. Viruses 7 (2013), 1202–1209.
32. Kasel, J.A., Couch, R.B., Gerin, J.L., Schulman, J.L., Effect of influenza anti-neuraminidase antibody on virus neutralization. Infect. Immun. 8 (1973), 130–131.
33. Couch, R.B., Atmar, R.L., Franco, L.M., Quarles, J.M., Wells, J., Arden, N., Nino, D., Belmont, J.W., Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J. Infect. Dis. 207 (2013), 974–981.
34. Corti, D., Suguitan, A.L. Jr, Pinna, D., Silacci, C., Fernandez-Rodriguez, B.M., Vanzetta, F., Santos, C., Luke, C.J., Torres-Velez, F.J., Temperton, N.J., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Investig. 120 (2010), 1663–1673.
35. Thomson, C.A., Wang, Y., Jackson, L.M., Olson, M., Wang, W., Liavonchanka, A., Keleta, L., Silva, V., Diederich, S., Jones, R.B., et al. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front. Immunol., 3, 2012, 87.
36. Ellebedy, A.H., Krammer, F., Li, G.M., Miller, M.S., Chiu, C., Wrammert, J., Chang, C.Y., Davis, C.W., McCausland, M., Elbein, R., et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 13133–13138.
37. 37• Nachbagauer, R., Kinzler, D., Choi, A., Hirsh, A., Beaulieu, E., Lecrenier, N., Innis, B.L., Palese, P., Mallett, C.P., Krammer, F., A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. npj Vaccines, 1, 2016, 16015 This study illustrates that inactivated influenza virus vaccines can be used to induce protective stalk-reactive antibodies in mice.
38. O'Hagan, D.T., Rappuoli, R., De Gregorio, E., Tsai, T., Del Giudice, G., MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines 10 (2011), 447–4462.
39. Roman, F., Clement, F., Dewe, W., Walravens, K., Maes, C., Willekens, J., De Boever, F., Hanon, E., Leroux-Roels, G., Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin. Vaccine Immunol. 18 (2011), 835–843.
40. Galson, J.D., Truck, J., Kelly, D.F., van der Most, R., Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination. Sci. Rep., 6, 2016, 37229.
41. Roy-Ghanta, S., Van der Most, R., Li, P., Vaughn, D.W., Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study. J. Infect. Dis. 210 (2014), 1419–1430.
42. Khurana, S., Verma, N., Yewdell, J.W., Hilbert, A.K., Castellino, F., Lattanzi, M., Del Giudice, G., Rappuoli, R., Golding, H., MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med., 3, 2011, 85ra48.
43. 43• Wang, Z., Wan, Y., Qiu, C., Quinones-Parra, S., Zhu, Z., Loh, L., Tian, D., Ren, Y., Hu, Y., Zhang, X., et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells. Nat. Commun., 6, 2015, 6833 This study illustrates the importance of CD8+ T cells for recovery from severe influenza disease in the absence of neutralizing antibodies in humans.
44. Bentebibel, S.E., Khurana, S., Schmitt, N., Kurup, P., Mueller, C., Obermoser, G., Palucka, A.K., Albrecht, R.A., Garcia-Sastre, A., Golding, H., et al. ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination. Sci. Rep., 6, 2016, 26494.
45. Bentebibel, S.E., Lopez, S., Obermoser, G., Schmitt, N., Mueller, C., Harrod, C., Flano, E., Mejias, A., Albrecht, R.A., Blankenship, D., et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci. Transl. Med., 5, 2013, 176ra132.
46. Trieu, M.C., Zhou, F., Lartey, S., Jul-Larsen, A., Mjaaland, S., Sridhar, S., Cox, R.J., Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination. J. Infect. Dis. 215 (2017), 740–749.
47. Kuriakose, T., Man, S.M., Malireddi, R.K., Karki, R., Kesavardhana, S., Place, D.E., Neale, G., Vogel, P., Kanneganti, T.D., ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Sci. Immunol., 1, 2016.
48. Thapa, R.J., Ingram, J.P., Ragan, K.B., Nogusa, S., Boyd, D.F., Benitez, A.A., Sridharan, H., Kosoff, R., Shubina, M., Landsteiner, V.J., et al. DAI senses influenza A virus genomic RNA and activates RIPK3-dependent cell death. Cell Host Microbe 20 (2016), 674–681.